Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for parkinson
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on parkinson and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Opicapone (Ongentys) - To treat patients with Parkinson’sdisease experiencing “off” episodes Drug Approval Package: ONGENTYS U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ONGENTYS Company: Neurocrine Biosciences, Inc. Application Number: 212489 Approval Date: 04/24/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson'sDisease. We report the implantation of patient-derived midbrain dopaminergic progenitor cells, differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient with idiopathic Parkinson'sdisease. The patient-specific progenitor cells were produced under Good Manufacturing Practice conditions and characterized as having the phenotypic properties of substantia nigra pars compacta neurons; testing (...) in a humanized mouse model (involving peripheral-blood mononuclear cells) indicated an absence of immunogenicity to these cells. The cells were implanted into the putamen (left hemisphere followed by right hemisphere, 6 months apart) of a patient with Parkinson'sdisease, without the need for immunosuppression. Positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine suggested graft survival. Clinical measures of symptoms of Parkinson'sdisease after surgery stabilized or improved
Isradipine Versus Placebo in Early ParkinsonDisease: A Randomized Trial. Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinsondisease (PD).To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD.Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842).57 Parkinson Study Group sites in North America.Patients (...) with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment.5 mg of immediate-release isradipine twice daily or placebo for 36 months.The primary outcome was change in the Unified Parkinson'sDisease Rating Scale (UPDRS) parts I to III score measured in the antiparkinson medication "ON" state between baseline and 36 months. Secondary outcomes included time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor
Diagnosis and Treatment of ParkinsonDisease: A Review. Parkinsondisease is the most common form of parkinsonism, a group of neurological disorders with Parkinsondisease-like movement problems such as rigidity, slowness, and tremor. More than 6 million individuals worldwide have Parkinson disease.Diagnosis of Parkinsondisease is based on history and examination. History can include prodromal features (eg, rapid eye movement sleep behavior disorder, hyposmia, constipation), characteristic (...) movement difficulty (eg, tremor, stiffness, slowness), and psychological or cognitive problems (eg, cognitive decline, depression, anxiety). Examination typically demonstrates bradykinesia with tremor, rigidity, or both. Dopamine transporter single-photon emission computed tomography can improve the accuracy of diagnosis when the presence of parkinsonism is uncertain. Parkinsondisease has multiple disease variants with different prognoses. Individuals with a diffuse malignant subtype (9%-16
Assessment of an Objective Method of Dyskinesia Measurement in Parkinson'sDisease. The goal of this study was to validate an objective method of measuring levodopa induced dyskinesia in Parkinson'sdisease (PD).To characterize agreement between the clinician-based measure and a force plate, we assessed dyskinesia in PD subjects participating in a randomized and blinded clinical trial of an adenosine A2A anatagonist. Convergent validity and intra-class correlations were evaluated between
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with ParkinsonDisease. Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end-organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the treatment of symptomatic nOH in adults. As the largest subpopulation of patients with nOH has a diagnosis of Parkinsondisease (PD
Istradefylline (Nourianz) - Parkinson'sdisease CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022075Orig1s000 CLINICAL REVIEW(S) (b) (4) Clinical Review Natalie Branagan, MD NDA 022075 Nourianz/istradefylline CLINICAL REVIEW Application Type NDA Application Number(s) 022075 Priority or Standard Class 2 Resubmission Submit Date(s) February 27, 2019 Received Date(s) February 27, 2019 PDUFA Goal Date August 27, 2019 Division/Office DNP Reviewer Name(s) Natalie Branagan, MD Review (...) Completion Date August 26, 2019 Established/Proper Name Istradefylline (Proposed) Trade Name Nourianz Applicant Kyowa Kirin Inc Dosage Form(s) Tablets Applicant Proposed Dosing Administer 20 mg orally once daily. The dose may be increased Regimen(s) to 40 mg once daily based on Applicant Proposed Adjunctive treatment to levodopa/carbidopa in adult patients Indication(s)/Population(s) with Parkinson’sdisease experiencing “OFF” episodes. Recommendation on There do not appear to be safety concerns
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson'sdisease: a double-blind, randomised controlled trial High-intensity aerobic exercise might attenuate the symptoms of Parkinson'sdisease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise-gamified and delivered at home, to promote adherence-on relieving motor symptoms in patients with Parkinson'sdisease with mild (...) disease severity who were on common treatment regimes.In this single-centre, double-blind, randomised controlled trial (Park-in-Shape), we recruited sedentary patients with Parkinson'sdisease from the outpatient clinic at Radboudumc, Nijmegen, Netherlands. Patients were made aware of the study either by their treating neurologist or via information in the waiting room. Patients could also contact the study team via social media. We included patients aged 30-75 years with a Hoehn and Yahr stage of 2
Canadian guideline for Parkinsondisease APPENDIX 1: CANADIAN GUIDELINE FOR PARKINSONDISEASE, 2 ND EDITION www.parkinson.ca www.ParkinsonClinicalGuidelines.ca Parkinson-final-E.indd 1 2019-09-05 2:39 PMNote: This full version of the Canadian Guideline for ParkinsonDisease has been copyedited to be consistent with the summary article published in CMAJ, but has not been peer reviewed. English printed: 978-1-897490-48-8 English electronic: 978-1-897490-49-5 Parkinson-final-E.indd 2 2019-09-05 2 (...) :39 PMTABLE OF CONTENTS Parkinson-final-E.indd 3 2019-09-05 2:39 PMINTRODUCTION ________________ 6 COMMUNICATION ____________ 12 DIAGNOSIS AND PROGRESSION _______________ 15 TREATMENT _________________ 19 NONMOTOR FEATURES OF PARKINSONDISEASE _______ 28 PALLIATIVE CARE _____________ 36 SUPPLEMENTAL MATERIAL _____ 38 REFERENCES _________________ 51 COMMUNICATION n People with Parkinsondisease should be encouraged to participate in choices about their own care. n Communication should be in verbal
Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson'sdisease Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson'sdisease | Report | National Health Care Institute You are here: Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson'sdisease Search within English part of National Health Care Institute Search Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson'sdisease
Safinamide (Onstryv) - idiopathic Parkinson'sdisease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1
Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in ParkinsonDisease: A Randomized Controlled Trial Freezing of gait (FOG) is one of the most disabling symptoms of Parkinsondisease (PD). Different land-based rehabilitation approaches based on motor and cognitive strategies can be effective in treating FOG. Although there are data about the efficacy of aquatic therapy in ameliorating this phenomenon, no study has explored the combined (...) effect of land-based therapies plus aquatic therapy in patients with PD who have FOG.The objective was to investigate the effectiveness of a multidisciplinary, intensive, motor-cognitive rehabilitation treatment (MIRT) in improving FOG and whether implementation with aquatic therapy (MIRT-AT) adds further benefits.The design consisted of a single-blind, parallel-group, 1:1 allocation ratio, randomized trial.The Department of ParkinsonDisease, Movement Disorders and Brain Injury Rehabilitation
Randomized trial of care management to improve Parkinsondisease care quality To test effects on care quality of Chronic Care Model-based Parkinsondisease (PD) management.This 2-group stratified randomized trial involved 328 veterans with PD in southwestern United States. Guided care management, led by PD nurses, was compared to usual care. Primary outcomes were adherence to 18 PD care quality indicators. Secondary outcomes were patient-centered outcome measures. Data sources were telephone (...) of the changes over time was in the positive Patient Health Questionnaire-2 depression screen for intervention minus usual care (-11.52 [95% CI -20.42, -2.62]).A nurse-led chronic care management intervention, Care Coordination for Health Promotion and Activities in Parkinson'sDisease (CHAPS), substantially increased adherence to PD quality of care indicators among veterans with PD, as documented in the EMR. Of 8 secondary outcomes assessed, a screening measure for depressive symptomatology was the only
Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With ParkinsonDisease: Randomized Controlled Pilot Study Declining physical activity commonly occurs in people with Parkinsondisease (PD) and contributes to reduced functional capacity and quality of life.The purpose of this study was to explore the preliminary effectiveness, safety, and acceptability of a mobile health (mHealth)-mediated exercise program designed to promote sustained physical (...) . Daily steps and moderate-intensity minutes were measured using a step activity monitor for 1 week at baseline and again at 12 months. Secondary outcomes included the 6-Minute Walk Test, ParkinsonDisease Questionnaire 39 mobility domain, safety, acceptability, and adherence.Both groups increased daily steps, moderate-intensity minutes, and 6-Minute Walk Test, with no statistically significant between-group differences observed. In the less active subgroup, changes in daily steps and moderate
Bright light therapy for depression in Parkinsondisease: A randomized controlled trial To assess the efficacy of bright light therapy (BLT) in reducing depressive symptoms in patients with Parkinsondisease (PD) and major depressive disorder (MDD) compared to a control light.In this double-blind controlled trial, we randomized patients with PD and MDD to treatment with BLT (±10,000 lux) or a control light (±200 lux). Participants were treated for 3 months, followed by a 6-month naturalistic
Trunk Exercises Improve Gait Symmetry in ParkinsonDisease: A Blind Phase II Randomized Controlled Trial. Deficits in step-to-step symmetry and trunk muscle activations have been linked to falls in Parkinsondisease. Given such symptoms are poorly managed with anti-parkinsonian medications, alternate therapies are needed. This blind phase II randomized controlled trial sought to establish whether exercise can improve step-to-step symmetry in Parkinson disease.Twenty-four Parkinsondisease (...) , active interventions seem more suited to increasing independence and quality of life for people with Parkinson disease.Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to do the following: (1) Describe the effect deficits in trunk muscle function have on gait in individuals with Parkinsondisease; (2) Identify the benefits of targeted trunk exercises on step-to-step symmetry